The reduction in price target by Oppenheimer, a reputable financial institution, could lead to a negative perception among investors regarding ACADIA Pharmaceuticals' future financial performance and stock valuation. This adjustment reflects a less optimistic outlook on the company's stock, potentially influencing short-term trading behavior negatively.